title: IL-6 is a key factor in growth inhibition of human myeloma cells induced by pravastatin, an HMG-CoA reductase inhibitor.
abstract: Although recent developments in initial chemotherapeutic regimens and stem cell transplantation have achieved improvements of initial remission for myeloma patients, relapse and recurrence are still major problems. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have been developed for treating hyperlipidemia. Recently, there have been several reports concerning the effects of statins on cancer cells including liver, colon, leukemia, malignant B, stomach, and breast cells. In this study, the in vitro effects of pravastatin on human myeloma cells and the factors closely related to its growth inhibitory effects were examined. Although concentrations were higher than those used clinically, 4 out of 10 myeloma lines showed growth inhibition by pravastatin. The study of factors related to the inhibition indicated IL-6 is important. Indeed, rhIL-6 abolished pravastatin-induced growth inhibition in KMS-21BM cells which did not express IL-6. Statins may be useful in maintenance therapy for myeloma after the screening of IL-6 status.
authors.affiliation: Department of Hygiene, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-0192, Japan. takemi@med.kawasaki-m.ac.jp
authors.forename: Takemi
authors.initials: T
authors.lastname: Otsuki
authors.forename: Haruko
authors.initials: H
authors.lastname: Sakaguchi
authors.forename: Masaaki
authors.initials: M
authors.lastname: Eto
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Fujii
authors.forename: Tamayo
authors.initials: T
authors.lastname: Hatayama
authors.forename: Akiko
authors.initials: A
authors.lastname: Takata
authors.forename: Takayuki
authors.initials: T
authors.lastname: Tsujioka
authors.forename: Takashi
authors.initials: T
authors.lastname: Sugihara
authors.forename: Fuminori
authors.initials: F
authors.lastname: Hyodoh
mesh_terms: D001973:Bromodeoxyuridine / Q000494:pharmacology; D002453:Cell Cycle; D002455:Cell Division; D045744:Cell Line, Tumor; D004396:Coloring Agents / Q000494:pharmacology; D018076:DNA, Complementary / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005434:Flow Cytometry; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000378:metabolism*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D015850:Interleukin-6 / Q000378:metabolism / Q000502:physiology*; D009101:Multiple Myeloma / Q000378:metabolism / Q000473:pathology*; D017035:Pravastatin / Q000494:pharmacology*; D012313:RNA / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014867:Water / Q000737:chemistry
chemical_list: D004396:Coloring Agents; D018076:DNA, Complementary; D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D015850:Interleukin-6; D014867:Water; D012313:RNA; D006903:Hydroxymethylglutaryl CoA Reductases; D001973:Bromodeoxyuridine; D017035:Pravastatin